Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $0.11.

  • Mimedx's EPS (Weighted Average and Diluted) rose 12000.0% to $0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.27, marking a year-over-year decrease of 5263.16%. This contributed to the annual value of $0.28 for FY2024, which is 3447.15% down from last year.
  • As of Q3 2025, Mimedx's EPS (Weighted Average and Diluted) stood at $0.11, which was up 12000.0% from $0.06 recorded in Q2 2025.
  • Mimedx's 5-year EPS (Weighted Average and Diluted) high stood at $0.34 for Q4 2023, and its period low was -$0.11 during Q1 2022.
  • For the 5-year period, Mimedx's EPS (Weighted Average and Diluted) averaged around $0.02, with its median value being $0.05 (2024).
  • In the last 5 years, Mimedx's EPS (Weighted Average and Diluted) plummeted by 26666.67% in 2022 and then skyrocketed by 180000.0% in 2023.
  • Quarter analysis of 5 years shows Mimedx's EPS (Weighted Average and Diluted) stood at -$0.02 in 2021, then changed by 0.0% to -$0.02 in 2022, then skyrocketed by 1800.0% to $0.34 in 2023, then plummeted by 85.32% to $0.05 in 2024, then skyrocketed by 120.43% to $0.11 in 2025.
  • Its EPS (Weighted Average and Diluted) was $0.11 in Q3 2025, compared to $0.06 in Q2 2025 and $0.05 in Q1 2025.